Catalyst Funds Management Pty Ltd
Position in AMRX — Amneal Pharmaceuticals, Inc.
CIK 1896150
SYDNEY NSW, C3
Position in AMRX
as of Jun 30, 2026
· filed Aug 10, 2026
Position Value
$292,539
+$38,967 QoQ
Shares Held
16,900
-17.2% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#192
of 305 holders
Holding Since
Mar 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in AMRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Catalyst Funds Management Pty Ltd holds $2,610,858 across 5 Drug Manufacturers - Specialty & Generic names. AMRX ranks #4 (11.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
13,400 | $856,930 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
1,441 | $780,777 | |
| 3 | NBIX |
Neurocrine Biosciences Inc
|
2,600 | $438,204 | |
| 4 | AMRX |
Amneal Pharmaceuticals, Inc.
This page
|
16,900 | $292,539 | |
| 5 | ELAN |
Elanco Animal Health Inc
|
9,850 | $242,408 |
All Filings in AMRX
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $292,539 | 16,900 | Shares | Sole | 2026-08-10 | |
| 2026-03-31 | $253,572 | 20,400 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $212,940 | 16,900 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $169,169 | 16,900 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $313,083 | 38,700 | Shares | Sole | 2025-08-12 | |
| 2024-03-31 | $63,024 | 10,400 | Shares | Sole | 2024-12-05 | |
| No filing history on record for this holder in this stock. | ||||||